Idexx Laboratories (IDXX) reported $4.3B in revenue for fiscal 2025, +10.4% year on year. That ranks #893 by revenue among 2853 SEC filers and #77 in Healthcare. Net income was $1.1B, a net margin of 24.6%. Revenue has grown 10.3% a year on average since 2016 ($1.8B then). The fiscal 2025 balance sheet shows $3.4B in total assets, $180M in cash and $375M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $4.3B | +10.4% | FY20252025-12-31 |
| Gross profitGrossProfit | $2.7B | +11.8% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $1.4B | +20.5% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $1.1B | +19.3% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.2B | +27.2% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $125M | +3.1% | FY20252025-12-31 |
| Total assetsAssets | $3.4B | +1.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.6B | +0.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $180M | −37.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $375M | −16.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $1.1B | $278M | Open → |
| Q2 20262026-06-30 | $1.2B | $338M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 20 of 161 companies compared | 24.6% | |
| Operating marginRank 15 of 160 companies compared | 31.6% | |
| R&D as share of revenueRank 70 of 102 companies compared | 5.8% | |
| Cash as share of revenueRank 127 of 160 companies compared | 4.2% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Idexx Laboratories Inc
- Ticker
- IDXX
- Exchange
- Nasdaq
- SIC classification
- In Vitro & In Vivo Diagnostic Substances (2835)
- Fiscal year end
- 12-31
- CIK
- 0000874716
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 20, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Elanco Animal HealthELAN | $4.7B | −$232M |
| DexcomDXCM | $4.7B | $836M |
| Cno FinancialCNO | $4.5B | $229M |
| Idexx LaboratoriesIDXX | $4.3B | $1.1B |
| Jazz PharmaceuticalsJAZZ | $4.3B | −$356M |
| PerrigoPRGO | $4.3B | −$1.4B |
| Cooper CompaniesCOO | $4.1B | $375M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Idexx Laboratories — Key figures |url=https://companiesranked.com/en/company/idexx-laboratories |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Idexx Laboratories — Key figures. CompaniesRanked. https://companiesranked.com/en/company/idexx-laboratoriesBibTeX
@misc{companiesranked-en-company-idexx-laboratories-2026,
author = {{CompaniesRanked}},
title = {{Idexx Laboratories — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/idexx-laboratories}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000874716-26-000038 · February 20, 2026
{{cite web |title=Idexx Laboratories — Key figures — 10-K (0000874716-26-000038) |url=https://www.sec.gov/Archives/edgar/data/874716/000087471626000038/idxx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-20}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.